Loans Payable

12 Months Ended

Jan. 31, 2026

6. Loans Payable

	BetterLife $			MedMelior $			Loans Payable $

Balance, January 31, 2023		40,000			40,000			80,000
Accretion and interest		1,248			1,247			2,495

Balance, January 31, 2024		41,248			41,247			82,495
Interest payment		(3,025	)		(2,268	)		(5,293	)
Accretion and interest		10,983			10,983			21,966

Balance, January 31, 2025		49,206			49,962			99,168
Loan extinguishment		–			(9,949	)		(9,949	)
Interest payment		(3,000	)		(3,660	)		(6,660	)
Principal payment		–			(4,928	)		(4,928	)
Accretion and interest		12,492			11,349			23,841

Balance, January 31, 2026		58,698			42,774			101,472

Current, January 31, 2026		58,698			15,600			74,298
Non-current, January 31, 2026		–			27,174			27,174

Balance, January 31, 2026		58,698			42,774			101,472

In February 2021, the Company and its subsidiary, MedMelior, each entered into Canada Emergency Business Account (“CEBA”) term loan agreements for $60,000 with an initial expiry date of December 31, 2022 (amended to January 18, 2024) and interest rate of nil% per annum during this initial term.

The Company’s CEBA term loan matures on December 31, 2026 and has an interest rate of 5% per annum.

MedMelior’s CEBA term loan has an interest rate of 5% per annum. In September 2025, MedMelior’s CEBA term loan was modified with the following new terms: Repayment of $1,300 per month through September 2027 and repayment of $28,658 on October 15, 2027. Pursuant to this modification, the Company recorded a gain on extinguishment of loan of $9,949 in its consolidated statements of loss and comprehensive loss during the year ended January 31, 2026 (2025 - $nil; 2024 - $nil).

Accretion for the year ended January 31, 2026 was $17,753 (2025 - $15,949; 2024 - $2,281). As at January 31, 2026, accrued interest of $90 (January 31, 2025 - $937) was included in loans payable.